TiGenix comments on rumors of a capital increase
Regulated information November 5, 2009
Leuven (BELGIUM) - November 5, 2009 - TiGenix comments on reports in the Flemish media regarding a potential capital increase.
With a cash position of 21.9 million EUR on September 30 2009, TiGenix has sufficient financial means at its disposal to finance its activities at least over the coming 12 months, not accounting the expected income generated by sales of ChondroCelect®.
TiGenix has the ambition to become an international player in the promising field of regenerative medicine. To finance its external growth, it might be necessary to raise additional financial means. Therefore, TiGenix does not rule out that the company will increase its capital if the market conditions are favorable.
Kind regards
Gil Beyen, CEO
T: +32 16 39 60 60
investor@tigenix.com
Leuven (BELGIUM) - November 5, 2009 - TiGenix comments on reports in the Flemish media regarding a potential capital increase.
With a cash position of 21.9 million EUR on September 30 2009, TiGenix has sufficient financial means at its disposal to finance its activities at least over the coming 12 months, not accounting the expected income generated by sales of ChondroCelect®.
TiGenix has the ambition to become an international player in the promising field of regenerative medicine. To finance its external growth, it might be necessary to raise additional financial means. Therefore, TiGenix does not rule out that the company will increase its capital if the market conditions are favorable.
Kind regards
Gil Beyen, CEO
T: +32 16 39 60 60
investor@tigenix.com
Subscribe to our newsletter
Stay tuned and get our news in your inbox: subscribe here.
Keep me informed
